High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity

Cardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the...

Full description

Bibliographic Details
Main Authors: George E. G. Kluck, Kristina K. Durham, Jeong-Ah Yoo, Bernardo L. Trigatti
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/full
_version_ 1818901996770426880
author George E. G. Kluck
Kristina K. Durham
Jeong-Ah Yoo
Bernardo L. Trigatti
author_facet George E. G. Kluck
Kristina K. Durham
Jeong-Ah Yoo
Bernardo L. Trigatti
author_sort George E. G. Kluck
collection DOAJ
description Cardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the most well-characterized of cardiotoxic anti-cancer therapies. While other anti-neoplastic drugs also induce cardiotoxicity, often leading to heart failure, they are beyond the scope of this review. This review first summarizes the mechanisms of doxorubicin-induced cardiotoxicity. It then reviews emerging preclinical evidence that high density lipoprotein and its precursor protein apolipoprotein A1, which are known for their protective effects against ischemic cardiovascular disease, may also protect against doxorubicin-induced cardiotoxicity both directly and indirectly, when used therapeutically.
first_indexed 2024-12-19T20:28:38Z
format Article
id doaj.art-094439669c184bbf882a618d79fc0e6a
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-12-19T20:28:38Z
publishDate 2020-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-094439669c184bbf882a618d79fc0e6a2022-12-21T20:06:47ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2020-04-01710.3389/fcvm.2020.00065520477High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated CardiotoxicityGeorge E. G. Kluck0Kristina K. Durham1Jeong-Ah Yoo2Bernardo L. Trigatti3Department of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaFaculty of Health Sciences, Institute of Applied Health Sciences, School of Rehabilitation Sciences, McMaster University, Hamilton, ON, CanadaDepartment of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaDepartment of Biochemistry and Biomedical Sciences, Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, CanadaCardiovascular disease and cancer are the leading causes of death in developed societies. Despite their effectiveness, many cancer therapies exhibit deleterious cardiovascular side effects such as cardiotoxicity and heart failure. The cardiotoxic effects of anthracyclines such as doxorubicin are the most well-characterized of cardiotoxic anti-cancer therapies. While other anti-neoplastic drugs also induce cardiotoxicity, often leading to heart failure, they are beyond the scope of this review. This review first summarizes the mechanisms of doxorubicin-induced cardiotoxicity. It then reviews emerging preclinical evidence that high density lipoprotein and its precursor protein apolipoprotein A1, which are known for their protective effects against ischemic cardiovascular disease, may also protect against doxorubicin-induced cardiotoxicity both directly and indirectly, when used therapeutically.https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/fullHDLApoA1anthracyclinchemotherapycardiotoxicitycardioprotective
spellingShingle George E. G. Kluck
Kristina K. Durham
Jeong-Ah Yoo
Bernardo L. Trigatti
High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
Frontiers in Cardiovascular Medicine
HDL
ApoA1
anthracyclin
chemotherapy
cardiotoxicity
cardioprotective
title High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
title_full High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
title_fullStr High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
title_full_unstemmed High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
title_short High Density Lipoprotein and Its Precursor Protein Apolipoprotein A1 as Potential Therapeutics to Prevent Anthracycline Associated Cardiotoxicity
title_sort high density lipoprotein and its precursor protein apolipoprotein a1 as potential therapeutics to prevent anthracycline associated cardiotoxicity
topic HDL
ApoA1
anthracyclin
chemotherapy
cardiotoxicity
cardioprotective
url https://www.frontiersin.org/article/10.3389/fcvm.2020.00065/full
work_keys_str_mv AT georgeegkluck highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity
AT kristinakdurham highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity
AT jeongahyoo highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity
AT bernardoltrigatti highdensitylipoproteinanditsprecursorproteinapolipoproteina1aspotentialtherapeuticstopreventanthracyclineassociatedcardiotoxicity